semaglutide compounding fda enforcement today Compounded The FDA has strictly clarified

Despite their popularity, GLP-1 agonists may contribute to the risk of kidney stone formation in some patients, particularly during the initial phases of treatment, but their long-term metabolic benefits may reduce stone risk over time

Data on this topic is limitedand much of the research conducted on it so far has been funded by pharmaceutical companies, FWIW

Novo Nordisk plans to sell a pill version of Wegovy, which will replace the injectable version currently on the market

Combining agents violates this on two fronts: it makes it impossible to isolate which compound is driving an observed effect, and it front-loads side effects before the body has adapted